Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969122 | 0.91 | HDAC6 (0.43) | GRM5HDAC6CYP1A2LMNATP53 | |
| SCHEMBL3313601 | 0.80 | L3MBTL1 (0.45) | KMT2AGAAMEN1 | |
| SCHEMBL27141147 | 0.76 | NR1H2 (0.45) | HDAC6LMNATP53KMT2AGAA | |
| SCHEMBL3309074 | 0.76 | CYP1A2 (0.40) | HDAC6CYP1A2KMT2AGAAMEN1 | |
| SCHEMBL2524047 | 0.75 | HDAC6 (0.70) | GRM5HDAC6LMNATP53KMT2A | |
| SCHEMBL25686948 | 0.75 | CYP1A2 (0.39) | HDAC6CYP1A2LMNATP53KMT2A | |
| SCHEMBL24812522 | 0.75 | RAB9A (0.37) | HDAC6CYP1A2LMNAKMT2AGAA | |
| SCHEMBL2527787 | 0.73 | GABRP (0.44) | GRM5HDAC6LMNAKMT2AALDH1A1 | |
| SCHEMBL25412001 | 0.73 | GRM5 (0.46) | GRM5HDAC6 | |
| SCHEMBL4751287 | 0.72 | L3MBTL1 (0.46) | GRM5CYP1A2KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | GRM5 296/4885HDAC6 2754/4885CYP1A2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.